The major trends in the antibody discovery space are related to
increasing interest in the applications of therapeutic antibodies and increased
investment by biotechnology and pharmaceutical companies.
• Growing demand for therapeutic antibodies: Therapeutic
antibodies are highly used in the treatment of many diseases and disease
conditions, including infections, malignancies, autoimmune disorders, and
cardiovascular diseases. One key benefit of using monoclonal antibody therapy
is that they have been used to make drugs that have been more successful at
treating specific diseases, like some cancers. The mechanism of action of
therapeutic antibodies includes neutralization to block the pathophysiological
function of their target molecules. Therapeutic antibodies are high molecular
weight biopharmaceuticals obtained by
culturing microorganisms and animal cells through genetic engineering. Due to
high specificity, target identification of the drug becomes clear, and higher
efficacy and fewer side effects can be expected.
• High research and development expenditure in pharmaceutical
and biotechnology companies: R&D expenditure in pharmaceutical and
biotechnology companies has a profound global impact. It advances global health
by developing treatments for a broad range of diseases and reduces the burden,
especially in developing countries, by tackling infectious diseases.
Biotechnology research and development is the process of creating new products,
technologies, and therapies using biological processes to solve challenges in
healthcare, agriculture, and environmental science. Research and development
are one of the biggest drivers of innovation in business. These can result in
the development of new products and services, enhanced processes, and new ways
to interact with customers.
Which potential factors impose significant concerns related to
the antibody discovery markets growth?
The
significant concerns related to growth in the antibody discovery sector relate
to the prohibitive costs of antibody production and increasing federal
regulations due to safety and disease transmission considerations.
• High cost involved in the antibody production:
Antibodies are expensive to produce. Most costs in monoclonal antibody
production include raw materials, labor, equipment, and facility expenses.
According to a report, the cost of antibody manufacturing generally exceeds $50
per gram of purified antibody or drug substance ($50/g of DS), which is far
higher than the target of $10/g of DS required to make them affordable in some
of the world’s poorest regions.
Source: - GCGH. Grand Challenges
• Stringent government regulations: Stringent government
regulations divert resources away from core business activities and
time-consuming and complex compliance processes. It may include limited
flexibility, interest rate risk, inflation risk, and lower returns. Government
reports may be biased or inaccurate, can be out of date, and non-specific to
the business.
Ready to Dive Deeper? Visit Here to Buy Databook and In-depth
Report Now! https://www.statifacts.com/order-databook/7769
Antibody
Discovery Market Report
Coverage:
|
Report
Attributes
|
Statistics
|
|
Market
Size in 2024
|
USD
8.21 Billion
|
|
Market
Size in 2025
|
USD
8.95 Billion
|
|
Market
Size in 2030
|
USD
14.04 Billion
|
|
Market
Size in 2032
|
USD
17 Billion
|
|
Market
Size by 2034
|
USD
20.43 Billion
|
|
CAGR
2025-2034
|
9.54%
|
|
Leading
Region in 2024
|
North
America
|
|
Fastest
Growing Region
|
Asia
Pacific
|
|
Base
Year
|
2024
|
|
Forecast
Years
|
2025-2034
|
|
Segments
Covered
|
Method,
Antibody Type, End-user, and Region
|
|
Region
Covered
|
North
America, Europe, Asia Pacific, Latin America, Middle East & Africa (MEA)
|
|
Key
Players
|
Eurofins
Scientific, Evotec, Twist Bioscience, Genscript Technology Corporation, Biocytogen,
Sartorius AG, Danaher Corporation, Fairjourney Biologics S.A, Creative
Biolabs, Charles River Laboratories
|
How Big Is the Development of the Antibody Discovery Platforms?
Antibody discovery platform allows specific, epitope-directed discovery for
optimal functionality, specificity, affinity, internalization, and
developability. Antibody discovery offers benefits like high stability, solubility,
and tissue penetration, making them attractive for therapeutic applications.
Antibody discovery platform addresses the challenges, including improving
binding precision & affinity, and design strategies for specific targets.
Antibody discovery improves sensitivity in diagnostics like affimer proteins as
synthetic antibodies, quantum plasmonic immunoassay sensing,
development of therapeutic antibodies, advancements in lateral flow assays
(LFAs), and improved antigen-antibody interaction.
Source: - Precision Antibody
How Big Is the Success of the North American Antibody Discovery Market?
North America dominated the global antibody discovery market share of 37% in
2024. Rising applications of monoclonal antibodies, booming biologics market, elevated
rate of approval and adoption in the U.S. & Europe, growing research and
development activities, as well as increasing use of these antibodies due to
their high specificity, allowing for precision therapies to combat several
diseases. These factors are driving expansion in the in North American market.
• In November 2024, the U.S. Food and Drug Administration (FDA)
accelerated approval of Ziihera 50mg/mL for injection for intravenous use for
the treatment of adults with previously treated unresectable or metastatic
HER2-positive (IHC 3+) biliary tract cancer (BTC), as detected by an
FDA-approved test, was announced by Jazz Pharmaceuticals, plc.
Source: - Jazz Pharmaceuticals
How is the Opportunistic Rise of the Asia
Pacific in the Antibody Discovery Market?
Asia Pacific is anticipated to grow at the fastest rate in the market during
the forecast period. Growing demand for therapeutic antibodies, increasing
R&D in pharmaceutical and biotechnology companies, and increasing adoption of personalized
medicine and companion diagnostics are contributing to the expansion of
the antibody discovery market in the Asia Pacific region.
How Is the State of the Antibody Discovery Market in China, India, and Japan?
• In October 2020, to develop SARS-CoV-2 neutralizing monoclonal
antibodies (mAbs) co-invented by the Scripps Research and International AIDS
Vaccine Initiative as innovative interventions to address the COVID-19
pandemic, International AIDS Vaccine Initiative, a non-profit research
organization aiming to address the urgent and unmet global health challenges
around the treatment of AIDS, and Serum Institute of India Pvt. Ltd, a major
manufacturer of biologics including vacines, announced an agreement with Merck
KGaA, Darmstadt, Germany, a leading science and technology company.
Source: - iavi
• In June 2025, the key technology of the independently
developed RenMab fully human antibody mouse platform has been granted an
innovation patent by the Japan Patent Office (JPO) was announced by Biocytogen
Pharmaceuticals (Beijing) Co., Ltd. This milestone denotes a significant leap
in strengthening the global intellectual property portfolio of the RenMice
fully human antibody platform family.
Source: - BusinessWire
Antibody Discovery Market Segmentation Analysis
Methods Analysis
Antibody Discovery Market Size by Methods, 2024 to 2034 (USD
Billion)
|
Segments
|
2024
|
2025
|
2026
|
2034
|
|
Phage
Display
|
4.134
|
4.427
|
4.743
|
8.609
|
|
Hybridoma
|
2.477
|
2.762
|
3.082
|
7.674
|
|
Others
|
1.596
|
1.759
|
1.938
|
4.146
|
The phage display segment held a dominant presence in the
antibody discovery market in 2024. One of the key benefits of phage display
is its unique characteristic to generate large libraries of diverse antibodies
relatively quickly. This is due to the technique involves inserting genes
encoding antibody fragments into bacteriophages, which are then used to create
a library of phages displaying many antibody fragments. Antibody phage display
(APD) allows in vitro selection of human mAbs of virtually any specificity and
affinity.
The hybridoma segment is expected to grow at the fastest rate in the market
during the forecast period of 2025 to 2034. Hybridoma techniques produce
monoclonal antibodies (mAb) by fusing a specific antibody-producing B-cell with
a myeloma cell, creating a hybrid cell called a hybridoma. Hybridoma technology
offers unlimited quantities of consistent, cost-effective, and homogenized
antibody production. Hybridoma is perfect for research, assay development, and
downstream research, diagnostic, and therapeutic uses.
Antibody Type Analysis
Antibody Discovery Market Size by Antibody Type, 2024 to 2034 (USD
Billion)
|
Segments
|
2024
|
2025
|
2026
|
2034
|
|
Humanized
Antibody
|
3.320
|
3.561
|
3.822
|
7.020
|
|
Human Antibody
|
2.154
|
2.340
|
2.545
|
5.178
|
|
Chimeric
Antibody
|
1.770
|
1.979
|
2.214
|
5.669
|
|
Murine
Antibody
|
0.963
|
1.068
|
1.183
|
2.562
|
The human antibody segment accounted for a considerable share of
the antibody discovery market in 2024. Fully human monoclonal
antibodies (mAbs) are derived completely from human subjects. These antibodies
mimic the structure and function of naturally occurring human immune proteins,
offering significant benefits in precision, safety, and therapeutic efficacy.
The human body has five different types of antibodies, including
immunoglobulins like IgA, IgD, IgG, IgE, and IgM are different immunoglobulin
isotypes.
The murine antibody segment is projected to experience the fastest rate of
market growth from 2025 to 2034. Murine antibodies are made by the immune
system in response to substances that are foreign to the organism. Donor
sources like mice and rats are being used for the production of specific
antibodies. Murine antibodies are engineered to reduce their natural
immunogenicity towards human patients.
End-users Analysis
Antibody Discovery Market Size by End-users, 2024 to 2034 (USD Billion)
|
Segments
|
2024
|
2025
|
2026
|
2034
|
|
Pharmaceutical
and Biotechnology industry
|
3.362
|
3.563
|
3.780
|
6.352
|
|
Research
laboratory
|
2.841
|
3.181
|
3.565
|
9.158
|
|
Others
|
2.004
|
2.203
|
2.419
|
4.919
|
The pharmaceutical & biotechnology industry segment led the
antibody discovery market. Antibodies are used in biotechnology in tests to
detect and monitor infectious agents like HIV, the cause of AIDS, or the
influenza virus causing pandemic flu, and for identifying diseases released by
biological weapons like anthrax and smallpox.
The academic laboratory segment is set to experience the highest
growth rate of the market between 2025 to 2034. Antibodies are the immune
system’s way of protecting us from infections, allergens, and toxins.
Antibodies are an increasingly indispensable component in several diagnostic
assays. Antibody uses include the detection of infections, the idenficiation of
allergens, and the measurement of hormones and other biological markers in
blood.
See More Related Reports:
• The U.S. antibody drug
conjugates market size was estimated at USD 4,020 million in
2024 and is projected to be worth around USD 12,050 million by 2034, growing at
a CAGR of 11.6% from 2024 to 2034.
• The global anti neurofilament L antibody market size was valued at USD
323 million in 2024 and is predicted to gain around USD 807.81 million by 2034
with a CAGR of 9.6%.
• The U.S. biosimilar monoclonal
antibody market size accounted for USD 3,210 million in 2024
and is expected to exceed around USD 26,500 million by 2034, growing at a CAGR
of 23.5% from 2025 to 2034.
• The global eDiscovery market size is
calculated at USD 13,141 million in 2024 and is predicted to attain around USD
29,439 million by 2034, expanding at a CAGR of 8.4% from 2024 to 2034.
• The global drug discovery market size is
calculated at USD 65.88 billion in 2024 and is predicted to reach around USD
160.31 billion by 2034, expanding at a CAGR of 9.3% from 2024 to 2034.
• The global cloud-based drug discovery platform
market
size is predicted to gain around USD 8,029 million by 2034 from USD 2,429
million in 2024 with a CAGR of 12.7%.
Competitive Landscape in the Antibody Discovery Market
• Danaher Corporation: Danaher is a leading innovator in
life sciences and diagnostics worldwide, committed to harnessing the tools of
science and technology to improve human health.
• Eurofins Scientific: Eurofins Scientific is a national
leader in laboratory services, serving food, environment, pharmaceutical, and
agroscience customers.
• Evotec: Evotec is a large drug discovery and
development company which often collaborates with other players in the space.
It discovers and develops small-molecule drugs spanning various disease areas.
• Twist Bioscience: This is a biotechnology company that
offers synthetic DNA solutions, gene synthesis, and variant libraries.
• Charles River Laboratories: Charles River
Laboratories supplies essential products and services to assist many
healthcare-related government agencies, pharmaceutical and biotechnology
companies, and leading academic institutions around the world in accelerating
their research undertakings and drug development efforts.
• Genscript Technology Corporation: Genscript Technology
Corporation accelerates innovation in biotechnology and healthcare by providing
researchers and companies with the building blocks needed to develop
groundbreaking treatments and products.
• Biocytogen: Biocytogen provides integrated solutions
for next-generation antibody drug development to the global biomedical
communities.
• Sartorius AG: Sartorius AG is a Germany-based supplier
of pharmaceutical and laboratory equipment.
• Fairjourney Biologics S.A.: They specialize in
customized services and technologies for optimal antibody solutions.
• Creative Biolabs: They offer world-class, cutting-edge
recombinant antibodies for biomedical research.
What Is Going Around the Globe in the Antibody Discovery Market?
• In June 2025, an innovative new resin to help achieve cost
savings and improve operations throughout the antibody manufacturing process
was launched by Ecolab Life Sciences.
Source: - Cleanroom Technology
• In May 2025, the global IDeate-Esophageal01 Phase 3 trial of a
new antibody drug conjugate in advanced esophageal squamous cell carcinoma was
launched by Merck and Daiichi Sankyo.
Source: - Applied Clinical Trials Online
Antibody Discovery Market Segments Covered in the Report
By Methods
• Phage Display
• Hybridoma
• Others
By Antibody Type
• Humanized Antibody
• Human Antibody
• Chimeric Antibody
• Murine Antibody
By End Users
• Pharmaceutical and Biotechnology industry
• Research laboratory
• Others
By Geography
• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East and Africa
Ready
to Dive Deeper? Visit Here to Buy Databook and In-depth Report Now! https://www.statifacts.com/stats/databook-download/7769
𝐀𝐛𝐨𝐮𝐭 𝐔𝐬:
Statifacts is a global
market intelligence and consulting leader, committed to delivering deep
strategic insights that fuel innovation and transformation. With a sharp focus
on the fast-evolving landscape of life sciences, we excel at navigating the
intricacies of cell and gene therapies, oncology, and drug
development. We empower our clients, ranging from biotech pioneers to
institutional investors with the intelligence needed to lead in high-impact
areas like regenerative medicine, cancer therapeutics, and precision health.
Our broad expertise across the pharma-biotech value chain is backed by robust,
statistically driven data for every market we cover, ensuring decisions are
informed, forward-looking, and built for impact.
Statifacts offers subscription services for data and analytics
insights. This page provides options to explore and purchase a subscription tailored
to your needs, granting access to valuable statistical resources and tools.
Access here - https://www.statifacts.com/get-a-subscription
Connect with Us
Ballindamm 22, 20095 Hamburg, Germany
Europe: +44 7383092044
Web: https://www.statifacts.com/
For Latest Update Follow Us: https://www.linkedin.com/company/statifacts
Our Trusted Data Partners:
Precedence Research | Towards Healthcare | Nova One Advisor
